OTCMKTS:PXXLF - Poxel Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$9.03 0.00 (0.00 %)
(As of 03/26/2019 04:00 PM ET)
Previous Close$9.03
Today's Range$9.03 - $9.03
52-Week Range$5.85 - $9.03
Volume42 shs
Average Volume68 shs
Market Capitalization$221.78 million
P/E RatioN/A
Dividend YieldN/A
Poxel SA, a biopharmaceutical company, develops drugs for metabolic diseases with a primary focus on type II diabetes. Its lead product is Imeglimin, an oral anti-diabetic candidate, which is in Phase III clinical development stage that targets the organs of diabetes, such as pancreas, liver, and muscles. The company is also developing PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in Phase IIa clinical trial that controls body energy metabolism and treats chronic metabolic diseases, such as non-alcoholic steatohepatitis. Poxel SA has a licensing agreement with Enyo Pharmaceuticals for the development of PXL007 (EYP001), an FXR agonist that is in Phase I study for the treatment of Hepatitis B. The company was founded in 2009 and is headquartered in Lyon, France.

Receive PXXLF News and Ratings via Email

Sign-up to receive the latest news and ratings for PXXLF and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations



Sales & Book Value

Annual SalesN/A



Market Cap$221.78 million
Next Earnings Date6/20/2019 (Estimated)
OptionableNot Optionable

Poxel (OTCMKTS:PXXLF) Frequently Asked Questions

What is Poxel's stock symbol?

Poxel trades on the OTCMKTS under the ticker symbol "PXXLF."

When is Poxel's next earnings date?

Poxel is scheduled to release their next quarterly earnings announcement on Thursday, June 20th 2019. View Earnings Estimates for Poxel.

Has Poxel been receiving favorable news coverage?

Media coverage about PXXLF stock has been trending negative this week, InfoTrie reports. The research group scores the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Poxel earned a coverage optimism score of -2.1 on InfoTrie's scale. They also gave headlines about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the next few days.

Who are some of Poxel's key competitors?

What other stocks do shareholders of Poxel own?

Who are Poxel's key executives?

Poxel's management team includes the folowing people:
  • Mr. Thomas Kuhn, Co-Founder, CEO & Director
  • Mr. Sébastien Bolze Pharm D Ph.D., Co-Founder & Exec. VP of Non Clinical Devel.
  • Ms. Pascale Fouqueray-Grellier, Co-Founder & Medical Director
  • Ms. Sophie Hallakou-Bozec, Co-Founder, EVP-Clinical Dev & Regulatory Affairs, SVP-R&D Pharmacology & Diabetes Research Director
  • Ms. Anne Renevot, Chief Financial Officer

How do I buy shares of Poxel?

Shares of PXXLF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Poxel's stock price today?

One share of PXXLF stock can currently be purchased for approximately $9.03.

How big of a company is Poxel?

Poxel has a market capitalization of $221.78 million.

MarketBeat Community Rating for Poxel (OTCMKTS PXXLF)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  41 (Vote Outperform)
Underperform Votes:  50 (Vote Underperform)
Total Votes:  91
MarketBeat's community ratings are surveys of what our community members think about Poxel and other stocks. Vote "Outperform" if you believe PXXLF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PXXLF will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/26/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel